Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | CKS1B | P61024 | 2/20 | 0.40 |
| ▸ | SKP1 | P63208 | 2/20 | 0.40 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4014808 | 1.00 | ESR2 (0.43) | ESR2GPR119NR1H2PDE10AMAP4K4 | |
| SCHEMBL4011248 | 1.00 | ESR2 (0.43) | ESR2GPR119NR1H2PDE10AMAP4K4 | |
| SCHEMBL4209371 | 1.00 | ESR2 (0.43) | ESR2GPR119NR1H2PDE10AMAP4K4 | |
| SCHEMBL4009809 | 0.90 | PIK3CD (0.42) | ESR2GPR119NR1H2PDE10AMAP4K4 | |
| SCHEMBL4202068 | 0.90 | PIK3CD (0.42) | ESR2GPR119NR1H2PDE10AMAP4K4 | |
| SCHEMBL4009808 | 0.90 | PIK3CD (0.42) | ESR2GPR119NR1H2PDE10AMAP4K4 | |
| SCHEMBL4206674 | 0.90 | GPR119 (0.46) | ESR2GPR119NR1H2PDE10AMAP4K4 | |
| SCHEMBL4015804 | 0.90 | PIK3CD (0.44) | ESR2GPR119NR1H2PDE10AMAP4K4 | |
| SCHEMBL4203467 | 0.90 | PIK3CD (0.44) | ESR2GPR119NR1H2PDE10AMAP4K4 | |
| SCHEMBL4015800 | 0.90 | PIK3CD (0.44) | ESR2GPR119NR1H2PDE10AMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | CASCADE THERAPEUTICS INC. (CA) | 2009-12-17 | — | — | US | disclosed |
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | CASCADE THERAPEUTICS INC. (CA) | 2009-12-17 | — | — | US | disclosed |
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | CASCADE THERAPEUTICS INC. (CA) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | HTR2C, HTR2A, HTR5A | ESR2 550/4885GPR119 220/4885NR1H2 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.